Register online | Log in | My Prescrire
Every month, the subjects in Prescrire’s Spotlight.
Editorial Welcome to the new, redesigned Prescrire International: a "critical eye" on drugs in Europe, with patients' interests front and centre.
1 January 2022
FEATURED REVIEW Is crizanlizumab more effective than hydroxycarbamide for patients with sickle-cell disease? Does it prevent vaso-occlusive crises and their serious complications when hydroxycarbamide is not sufficiently effective or cannot be used? What is its adverse effect profile? Full review (5 pages) available for download by subscribers.
FREE DOWNLOAD In our sample page from this month's issue, cardiac arrhythmias with lamotrigine, and biotin supplements' interference with laboratory tests. Full text available for free download.
Giving fenfluramine to children with Dravet syndrome (a rare and severe form of epilepsy), including those whose seizures remain frequent despite optimised treatment, increases the incidence of the most serious seizures and exposes them to a risk of serious cardiovascular adverse effects.
Errors and accidents are frequent with vitamin D supplied in dropper bottles. These include handling by children, eye exposure and, above all, overdose due to a mistake or related to a defective dropper bottle.
Despite aducanumab's lack of demonstrated efficacy in Alzheimer's disease, the scene is set to raise the hopes of patients and those close to them, and above all to promote the interests of the company and its shareholders.
COVID-19 Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view.